India’s First Dengue Vaccine, Qdenga, Arriving in 2024

Exciting news for India! A dengue vaccine, developed by Japanese pharmaceutical giant Takeda and produced in collaboration with Hyderabad-based Biological E (Bio E), is expected to be available as early as next year. This marks a significant step forward in the fight against dengue fever, a mosquito-borne illness that affects millions in India annually.

Qdenga: Protection Against All Four Dengue Serotypes

The vaccine, known as Qdenga, is designed to provide broad protection against all four known serotypes of the dengue virus. This comprehensive approach is crucial, as infection with one serotype does not grant immunity against the others and can even increase the risk of severe complications upon subsequent infection with a different serotype.

Two-Dose Regimen for Effective Dengue Prevention

Qdenga will be administered in a two-dose schedule, further enhancing its effectiveness in preventing dengue fever. More details about the vaccination rollout, including pricing and availability, are expected to be released closer to the launch date.